苯并三唑-1-基氧基-三(二甲基氨基)鏻 | 56602-32-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并三唑类
• 中文名称: 苯并三唑-1-基氧基-三(二甲基氨基)鏻
• 英文名称: (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium salt
• 英文别名: Benzotriazolyl-N-oxytrisphosphonium；(benzotriazol-1-yloxy)tris(dimethylamino)phosphonium；Benzotriazol-1-yloxy-tris(dimethylamino)phosphonium；benzotriazol-1-yloxy-tris(dimethylamino)phosphanium
• CAS: 56602-32-5
• 化学式: C₁₂H₂₂N₆OP
• 分子量: 297.32
• InChiKey: RROBIDXNTUAHFW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  49.7
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  六氟磷酸盐 、 苯并三唑-1-基氧基-三(二甲基氨基)鏻 生成 卡特缩合剂
  参考文献：
  名称：

  NOVEL PEPTIDES, USE THEREOF IN COSMETIC AND COSMECEUTIC APPLICATIONS, AND COMPOSITIONS COMPRISING SAME

  摘要：

  序列编号为1的肽类分子式为I：Lip-A-Gly-His-B-R，其中：Lip是R或S构型的脂肪酰残基；A不存在或是L或D构型的赖氨酸残基；Gly是甘氨酸残基；His是L或D构型的组氨酸残基；B是L或D构型的赖氨酸残基，或是其侧链的NH2基团经修饰后的赖氨酸残基，该修饰是(i)用氢原子替换或(ii)用保护基选自乙酰基、苯甲酰基、托磺基苯、苄氧羰基和棕榈酰基的保护基进行修饰；其中R是O(Z)或N(Z′)(Z′)，Z、Z′和Z′独立地选自氢原子或选自甲基、乙基、丙基、苯基、己基、癸基和十六烷基的保护基，或是它们的外消旋体、对映体或二对映异构体的混合物，或是其盐。 序列编号为2的肽类分子式为II：Lip-A-His-B-C-Trp-R，其中：Lip是R或S构型的脂肪酰残基；His是L构型的组氨酸残基；Trp是L构型的色氨酸残基；A不存在，是选自L或D构型的氨基酸残基的赖氨酸残基、丙氨酸残基、谷氨酸残基和甘氨酸残基，或是分子式为NH—(CH2)n-CO—，其中n为2至14之间的整数的间隔物；B是D构型的芳香族氨基酸残基，选自苯丙氨酸残基、同型苯丙氨酸残基、色氨酸残基、β-(1-萘基)-丙氨酸残基、β-(2-萘基)-丙氨酸残基和苯基甘氨酸残基；C是L构型的碱性氨基酸残基，选自精氨酸残基、赖氨酸残基、鸟氨酸残基和同型精氨酸残基；其中R是O(Z)或N(Z′)(Z′)。

  公开号：

  US20100310484A1

文献信息

• Imidazo[1,2-a]pyridine derivative
  申请人：Takemura Makoto

  公开号：US20050113397A1

  公开（公告）日：2005-05-26

  A compound reprsented by the following formula (I), its salts or nsolvates thereof capable of specifically or selectively expressig an antifungal activity in a broad spectrum based on the novel mechanism thereof of 1,6-β-glucan synthesis inhibition, and an antifungal agent containing any of them.

  以下化学式（I）所代表的化合物，其盐或无溶剂物，能够基于其新颖的机制——1,6-β-葡聚糖合成抑制，具有广谱的特异性或选择性抗真菌活性，以及含有其中任何一种的抗真菌剂。
• Cb1 antagonist compounds
  申请人：Allen Rebecca Jennifer

  公开号：US20070088018A1

  公开（公告）日：2007-04-19

  Novel compounds of structural formula (I) are disclosed. As modulators of the Cannabinoid-1 (CB1) receptor, these compounds are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. As such, compounds of the present invention are useful as in the treatment, prevention and suppression of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders (e.g., multiple sclerosis, Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis), cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith.

  本发明揭示了化学结构式（I）的新型化合物。作为大麻素-1（CB1）受体的调节剂，这些化合物在治疗、预防和抑制由CB1受体介导的疾病方面具有用途。因此，本发明的化合物在治疗、预防和抑制精神病、记忆障碍、认知障碍、偏头痛、神经病、神经炎症性疾病（例如多发性硬化症、吉兰-巴雷综合征和病毒性脑炎的炎症后遗症）、脑血管意外、头部创伤、焦虑症、压力、癫痫、帕金森病和精神分裂症方面具有用途。这些化合物还可用于治疗物质滥用障碍，特别是阿片类药物、酒精和尼古丁。这些化合物还可用于治疗与过度食物摄入及其并发症相关的肥胖症或进食障碍。
• Methods and apparatus for synthesizing labeled combinatorial chemistry libraries
  申请人：Discovery Partners International

  公开号：US06417010B1

  公开（公告）日：2002-07-09

  The present invention provides labeled synthetic libraries of random oligomers and methods and apparatus for generating labeled synthetic oligomer libraries. Each member of such a library is labeled with a unique identifier tag that specifies the structure or sequence of the oligomer. In a preferred embodiment of the present invention the identifier tag is a microchip that is pre-encoded or encodable with information that is related back to a detector when the identifier tag is pulsed with electromagnetic radiation.

  本发明提供了带标签的随机寡聚物合成库，以及生成带标签的合成寡聚物库的方法和装置。该库中的每个成员都带有唯一的标识符标签，该标签指定寡聚物的结构或序列。在本发明的首选实施例中，标识符标签是一种微芯片，可以预编码或可编码信息，当标识符标签被电磁辐射脉冲时，可以将信息与检测器相关联。
• Methods and apparatus for synthesizing labeled combinatorial chemistry
  申请人：Irori

  公开号：US06087186A1

  公开（公告）日：2000-07-11

  The present invention provides labeled synthetic libraries of random oligomers and methods and apparatus for generating labeled synthetic oligomer libraries. Each member of such a library is labeled with a unique identifier tag that specifies the structure or sequence of the oligomer. In a preferred embodiment of the present invention the identifier tag is a microchip that is pre-encoded or encodable with information that is related back to a detector when the identifier tag is pulsed with electromagnetic radiation.

  本发明提供了带标签的随机寡核苷酸合成文库，以及产生带标签的合成寡核苷酸文库的方法和装置。该文库中的每个成员都带有唯一的标识符标签，该标签指定了寡核苷酸的结构或序列。在本发明的一种优选实施例中，标识符标签是一种微芯片，可以预编码或编码与探测器相关的信息，当标识符标签脉冲电磁辐射时，可以将信息传回探测器。
• CB1 antagonist compounds
  申请人：Eli Lilly and Company

  公开号：US07276516B2

  公开（公告）日：2007-10-02

  Novel compounds of structural formula (I) are disclosed. As modulators of the Cannabinoid-1 (CB1) receptor, these compounds are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. As such, compounds of the present invention are useful as in the treatment, prevention and suppression of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders (e.g., multiple sclerosis, Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis), cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith

  揭示了结构式(I)的新型化合物。作为Cannabinoid-1（CB1）受体的调节剂，这些化合物在治疗、预防和抑制由CB1受体介导的疾病方面非常有用。因此，本发明的化合物在治疗、预防和抑制精神病、记忆障碍、认知障碍、偏头痛、神经病、神经炎症性疾病（例如多发性硬化症、格林-巴利综合征和病毒性脑炎的炎症后遗症）、脑血管意外、头部创伤、焦虑症、压力、癫痫、帕金森病和精神分裂症方面非常有用。这些化合物也可用于治疗物质滥用障碍，特别是阿片类、酒精和尼古丁。这些化合物也可用于治疗与过度进食和相关并发症相关的肥胖或进食障碍。